Tamar Dola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tamar Dola has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Assalia
Department of General Surgery, Rambam Health Care Campus and the Rappaport faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel
1 shared publication - Dan Hershko
Department of Surgery, Emek Medical Center, Afula, Israel
1 shared publication - Hadar Aboody-Nevo
Department of Surgery, Emek Medical Center, Afula, Israel
1 shared publication - Ian Mark Gralnek
Technion-Israel Institute of Technology
1 shared publication - Moaad Farraj
Department of Surgery, Galilee Medical Center, Nahariya, Israel
1 shared publication - Nasser Sakran
Holy Family Hospital, The Azireli Faculty of Medicine, Bar Ilan University, Nazareth, Israel
1 shared publication
Latest Publications
- 14 July 2020
- Published by Springer Nature in Updates in Surgery
- Vol. 72 (4) , 1125-1133
The use of Ursolit for gallstone prophylaxis following bariatric surgery: a randomized-controlled trial
Background Although bariatric surgery (BS) predisposes patients to development of gallstone formation, a preventive strategy is still in debate. Aim To compare the incidence of gallstone formation between patients treated with ursodeoxycholic acid (UDCA) vs. placebo for a duration of 6 months following BS. Methods This multicenter randomized, double-blind controlled trial entails treatment with UDCA vs. an identical-looking placebo. The primary outcome was gallstone formation, as measured by abdominal ultrasound. Results The data of 209 subjects were enrolled in the study, and 92 subjects completed the study and were analyzed (n = 46 for each study group). The high dropout rate was mainly due to difficulties in adding more medications and swallowing the pill. Among the subjects who completed the study, 77.2% were women, and their mean age and pre-surgery BMI were 42.2 ± 10.2 years and 44.4 ± 6.1 kg/m2, respectively. Gallstone formation was recorded in 45.7% (n = 21) vs. 23.9% (n = 11) of subjects among placebo vs. UDCA groups, respectively, p = 0.029. Subgroup-analysis, according to surgery type, found that the results were significant only for SG subjects (p = 0.041), although the same trend was observed for OAGB/RYGB. Excess Weight Loss percent (%EWL) at 6 months post-surgery was 66.0 ± 17.1% vs. 71.8 ± 19.5% for the placebo and UDCA groups, respectively; p = 0.136. A trend towards a reduction in prescribed comorbidity medications was noted within-groups during the follow-up period, as compared to baseline, with no between-group differences (p ≥ 0.246). Moreover, no between-group differences were found for blood test results (p ≥ 0.063 for all). Conclusion Administration of UDCA significantly decreased gallstone formation at 6 months at following BS. ClinicalTrials.gov number NCT02319629.
- 14 July 2020
- Published by Springer Nature in Updates in Surgery
- Vol. 72 (4) , 1125-1133
The use of Ursolit for gallstone prophylaxis following bariatric surgery: a randomized-controlled trial
Background Although bariatric surgery (BS) predisposes patients to development of gallstone formation, a preventive strategy is still in debate. Aim To compare the incidence of gallstone formation between patients treated with ursodeoxycholic acid (UDCA) vs. placebo for a duration of 6 months following BS. Methods This multicenter randomized, double-blind controlled trial entails treatment with UDCA vs. an identical-looking placebo. The primary outcome was gallstone formation, as measured by abdominal ultrasound. Results The data of 209 subjects were enrolled in the study, and 92 subjects completed the study and were analyzed (n = 46 for each study group). The high dropout rate was mainly due to difficulties in adding more medications and swallowing the pill. Among the subjects who completed the study, 77.2% were women, and their mean age and pre-surgery BMI were 42.2 ± 10.2 years and 44.4 ± 6.1 kg/m2, respectively. Gallstone formation was recorded in 45.7% (n = 21) vs. 23.9% (n = 11) of subjects among placebo vs. UDCA groups, respectively, p = 0.029. Subgroup-analysis, according to surgery type, found that the results were significant only for SG subjects (p = 0.041), although the same trend was observed for OAGB/RYGB. Excess Weight Loss percent (%EWL) at 6 months post-surgery was 66.0 ± 17.1% vs. 71.8 ± 19.5% for the placebo and UDCA groups, respectively; p = 0.136. A trend towards a reduction in prescribed comorbidity medications was noted within-groups during the follow-up period, as compared to baseline, with no between-group differences (p ≥ 0.246). Moreover, no between-group differences were found for blood test results (p ≥ 0.063 for all). Conclusion Administration of UDCA significantly decreased gallstone formation at 6 months at following BS. ClinicalTrials.gov number NCT02319629.